Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports

Gaspari, Valeria; Zengarini, Corrado; Greco, Sonia; Vangeli, Valeria; Mastroianni, Antonio

doi:10.1016/j.ijantimicag.2020.106023

Cited by 44 publications

(39 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from two other clinical studies with ruxolitinib were reported recently, plus a few single cases [56,57]. In the study of La Rosée et al [58], 14 COVID-19 patients with evidence of severe hyperinflammation, based on a newly developed COVID-19 Inflammation Score, received ruxolitinib over a median of 9 days and a median cumulative dose of 135 mg (approximately, 15 mg day).…”

Section: Discussionmentioning

confidence: 94%

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

et al. 2020

View full text Add to dashboard Cite

Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/ JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-use protocol. Patients had severe pulmonary disease defined by pulmonary infiltrates on imaging and an oxygen saturation ≤ 93% in air and/or PaO2/FiO2 ratio ≤ 300 mmHg. Median age was 80.5 years, and 85.3% had ≥ 2 comorbidities. Median exposure time to ruxolitinib was 13 days, median dose intensity was 20 mg/day. Overall survival by day 28 was 94.1%. Cumulative incidence of clinical improvement of ≥2 points in the ordinal scale was 82.4% (95% confidence interval, 71-93). Clinical improvement was not affected by low-flow versus highflow oxygen support but was less frequent in patients with PaO2/FiO2 < 200 mmHg. The most frequent adverse events were anemia, urinary tract infections, and thrombocytopenia. Improvement of inflammatory cytokine profile and activated lymphocyte subsets was observed at day 14. In this prospective cohort of aged and high-risk comorbidity patients with severe COVID-19, compassionate-use ruxolitinib was safe and was associated with improvement of pulmonary function and discharge home in 85.3%. Controlled clinical trials are necessary to establish efficacy of ruxolitinib in COVID-19.

show abstract

Section: Discussionmentioning

confidence: 94%

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…79% of the 14 pts received glucocorticoids 6 . Skin toxicity was observed upon ruxolitinib treatment in two hydrochloroquine/lopinavor/ritonavir‐pretreated pts with COVID‐19 7 . In a fourth report, two young pts in their 20´s with alopecia areata continued their treatment with ruxolitinib when they developed proven COVID‐19 and showed a mild COVID‐19 course 8 …”

Section: Resultsmentioning

confidence: 99%

Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis

Koschmieder

Jost

Cornelissen

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

Advanced age and comorbidities are risk factors for severe SARS-CoV-2 infection and development of ARDS. 1,2 Elevated inflammatory parameters such as an increased white blood cell (WBC) count, C-reactive protein (CRP), interleukin-6 (IL-6), and soluble IL-2 receptor correlate with ARDS and multiorgan failure (MOF) in COVID-19 patients, 2 comparable to the so-called "cytokine storm" syndrome. Frontline treatment of COVID-19 infection consists of supportive care. In addition, off-label and experimental treatment options

show abstract

“…Janus kinase signal inducer (JAK) pathway inhibitors, ruxolitiniband baricitinib, are also being investigated. [ 25 , 26 ] Convalescent plasma therapy also has potential, but safety and efficacy have to be established with larger studies. [27] , [28] , [29] …”

Section: Introductionmentioning

confidence: 99%

Stem cell therapy in coronavirus disease 2019: current evidence and future potential

et al. 2021

View full text Add to dashboard Cite

Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports

Cited by 44 publications

References 5 publications

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis

Stem cell therapy in coronavirus disease 2019: current evidence and future potential

Contact Info

Product

Resources

About